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3 
Abstract 
 
Objective 
To evaluate whether nephrotoxicity differs between nafcillin and piperacillin-tazobactam in adult 
hospitalized patients. 
 
Introduction 
Acute kidney injury (AKI) is a significant cause of morbidity and mortality in the inpatient 
setting, with antibiotics being a significant contributor. There is evidence of an increased risk of 
nephrotoxicity with the combination of vancomycin and piperacillin-tazobactam compared to 
vancomycin and cefepime or vancomycin alone. It is unknown whether this effect is exclusive 
for piperacillin-tazobactam. Therefore, in order to promote optimal medication therapy for 
inpatient bacterial infections, there is a need to assess the persistence of this difference in other 
beta-lactam antibiotics. 
 
Methods 
A single-center, retrospective cohort study was performed utilizing electronic health records at 
University of Kentucky Healthcare. Adult hospitalized patients being treated with nafcillin or 
piperacillin-tazobactam from September 1, 2010 to September 1, 2014 were included in the 
study. Age, sex, Charlson Comorbidity Index, baseline creatinine clearance, dehydration, 
hypotension, exposure to concomitant nephrotoxins, and duration of therapy were evaluated. The 
primary outcome was AKI as defined by the RIFLE criteria (risk, injury, failure, loss of kidney 
function, and end-stage kidney disease), where risk, injury, and failure were defined as a 25%, 
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50%, and 75% decrease in glomerular filtration rate from baseline, respectively. Secondary 
outcomes included time to AKI from initiation of antibiotics, hospital length of stay, and 
mortality. 
 
Results  
Of the 3,393 patients included in this study, 272 were treated with nafcillin and 3,121 were 
treated with piperacillin-tazobactam. Overall incidence of AKI was 19.49% in the nafcillin group 
and 7.72% in the piperacillin-tazobactam group (p<0.0001). After adjusting for age, sex, 
Charlson Comorbidity Index, baseline creatinine clearance, hypotension, number of concomitant 
nephrotoxins, and duration of therapy, those in the nafcillin group had 2.002 (95% CI 1.357-
2.953) times the odds of AKI compared to those in the piperacillin-tazobactam group. Time to 
AKI, hospital length of stay, and inpatient mortality were also significantly higher in the nafcillin 
group.  
 
Conclusions 
The results from this study suggest that nafcillin has a significantly greater potential for 
nephrotoxicity compared to piperacillin-tazobactam. Future research may involve further 
evaluating the risk factors of AKI, indication, and dosing schedule of these or other antibiotics in 
a larger population.   
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Introduction 
 
The incidence of acute kidney injury (AKI) is estimated to be between 5.7% and 18.0%. 
Development of AKI can lead to significant increases in length of stay, healthcare costs, and 
mortality, with in-hospital mortality ranging from 50.5% to 76.8%.1-3 AKI can occur as a result 
of a number of factors including cardiac insufficiency, sepsis, malignancy, liver insufficiency, 
and autoimmune diseases.3 Drug-induced nephrotoxicity is also a significant cause of AKI and 
has been shown to be associated with angiotensin-converting enzyme inhibitors (ACEIs), 
angiotensin receptor blockers (ARBs), acyclovir, aminoglycosides, amphotericin B, beta-lactam 
antibiotics, IV contrast, and non-steroidal anti-inflammatory drugs (NSAIDs), among others.4,5 
 
Piperacillin-tazobactam is a beta-lactam/beta-lactamase inhibitor combination broad-spectrum 
antibiotic commonly used to empirically treat for many gram-positive and gram-negative 
infections. Incidence of nephrotoxicity in piperacillin-tazobactam has been reported to be 9.0% 
to 18.2%.6-8 There is little data demonstrating the mechanism of nephrotoxicity of piperacillin-
tazobactam, although in few studies indicate acute interstitial nephritis (AIN) is the most likely 
cause.9-12,37 Piperacillin-tazobactam has also been shown to cause a lower rate of renal recovery 
compared to other antibiotics.13 
 
The combination of vancomycin, a glycopeptide antibiotic used to treat gram-positive infections, 
with piperacillin-tazobactam has a higher incidence of nephrotoxicity than vancomycin alone.14,15 
In yet to be published data from a study conducted at the University of Kentucky, the 
combination of vancomycin and piperacillin-tazobactam also had a higher incidence of 
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nephrotoxicity than combination of vancomycin and cefepime, another broad-spectrum beta-
lactam antibiotic. It is unknown whether this effect is exclusive for piperacillin-tazobactam or if 
it also exists in other beta-lactam antibiotics. 
 
Nafcillin is a narrow-spectrum beta-lactam antibiotic used most commonly as one of the first line 
treatments for methicillin-sensitive Staphylococcus aureus (MSSA) infections. Incidence of 
nephrotoxicity of nafcillin has been shown to be 11.4%.16 Nafcillin has been reported as the most 
probable cause of acute interstitial nephritis (AIN) in a number of cases.17-19  
 
The purpose of this study is to investigate the difference in nephrotoxicity between nafcillin and 
piperacillin-tazobactam in adult hospitalized patients. The results of this study may aid in the 
selection of medication therapy for inpatient bacterial infections. 
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Methods 
 
Study sample  
 
A single-center, retrospective cohort study was conducted at University of Kentucky Healthcare, 
a tertiary care academic medical center. All patients admitted between September 1, 2010 and 
September 1, 2014 without renal dysfunction at initiation, chronic kidney disease, structural 
kidney disease, or pre-existing dialysis were eligible for the study. Patients with kidney disease 
at baseline were excluded to allow for assessment of the effects of the study antibiotics. Each 
admission was treated as an independent event. Patients receiving either nafcillin or piperacillin-
tazobactam were included. Patients were excluded from the piperacillin-tazobactam group if they 
received therapy with vancomycin in order to isolate the effects of the study drug. Those in the 
nafcillin group may have received up to 5 days of vancomycin or piperacillin-tazobactam to 
remain in the study due to clinical use of nafcillin typically being after initial treatment with 
more broad-spectrum empiric therapy. Other exclusion criteria include length of stay less than 2 
days, age less than 18 years, baseline creatinine clearance greater than 4 times the standard 
deviation of the mean or less than 30 mL/min, days of antibiotic therapy less than 2 days, and 
AKI prior to treatment index, within 48 hours of treatment index, or greater than 7 days after 
treatment was discontinued. Minimum limits were used for length of stay and duration of 
antibiotic therapy to exclude AKI events due to previous exposures. These criteria were applied 
for timeframe of AKI to limit events to those that occurred due to the study drugs. Patients who 
did not have serum creatinine values were also excluded from analysis. This study was exempt 
from IRB approval as only de-identified data were used. 
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Data collection and measures 
 
Inpatient clinical data from September 1, 2010 to September 1, 2014 was gathered from the 
University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust. 
Information on age, sex, Charlson Comorbidity Index, baseline creatinine clearance, 
dehydration, hypotension, receipt of concomitant nephrotoxins, and duration of antibiotic 
therapy were collected. Many of these factors have the potential to increase risk of AKI. 
Charlson Comorbidity Index is a measure of illness severity based on a patient’s medical history. 
Baseline creatinine clearance was based on the first measured serum creatinine. Hypotension was 
determined by the composite of hypotension diagnosis, mean arterial pressure less than 60 
mmHg, and/or use of vasopressor or inotrope therapy. Concomitant nephrotoxins assessed 
include acyclovir, aminoglycosides, amphotericin B, ACEIs, ARBs, colistin, cyclosporine, 
foscarnet, IV contrast, loop diuretics, NSAIDS, sulfonamides, tacrolimus, and tenofovir. Patients 
received one point for each of the nephrotoxins studied to give a total number of concomitant 
nephrotoxins received. Duration of therapy was defined as the number of unique days patient 
received at least one dose of study antibiotic. 
 
Study outcomes 
 
The primary outcome was the difference in AKI between nafcillin and piperacillin-tazobactam as 
defined by the RIFLE criteria based on percent change from baseline creatinine clearance to 
minimum creatinine clearance. This was evaluated both in patients being treated with nafcillin 
with exposure to piperacillin-tazobactam and/or vancomycin for 5 days or less, as well as the 
9 
nafcillin only group. The RIFLE criteria is the first consensus definition of AKI.20 Within the 
RIFLE criteria there are 3 severity classes, risk, injury, and failure, which are a 25%, 50%, and 
75% decrease in glomerular filtration rate (GFR) from baseline. GFR is a measure of kidney 
function and is based on the adjusted Cockcroft-Gault equation. In addition, there are two 
outcome classes, loss of kidney function and end-stage kidney disease. The current study did not 
evaluate outcome classes because diagnosis based on duration of renal dysfunction is required, a 
variable that was not collected. The RIFLE criteria has been largely validated to identify AKI, 
classify severity, and correlate with patient outcome.21-24  
 
Secondary outcomes include time to AKI from initiation of antibiotic therapy, hospital length of 
stay, and mortality, where mortality is a composite of inpatient mortality and transfer to hospice 
service. 
 
Statistical analysis 
 
Basic descriptive statistics were used to assess the characteristics of the study population. 
Continuous variables were evaluated by Student’s T-test or, if data was not normally distributed, 
Wilcoxon Rank Sum test. Data from continuous variables were reported as mean and standard 
deviation as well as median with interquartile range. Categorical variables were analyzed using 
Chi-Square test or, if there was a count of less than 5 in one of the cells of the contingency table 
or if 25% or more cells had expected counts less than 5, results from Fisher's Exact test were 
reported. Data from categorical variables were reported as number and percentage. All tests were 
two-sided with significance defined as p < 0.05. Chi-Square test and Fisher’s Exact test were 
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also used for the unadjusted analysis of the primary outcome of AKI overall and for risk, injury, 
and failure classifications. Logistic regression was used for an adjusted analysis of the primary 
outcome of AKI overall and for risk, injury, and failure classifications. Adjustment was made for 
all variables that reached statistical significance in the bivariate analysis. Secondary outcomes 
were analyzed using Student’s T-test or Wilcoxon Rank Sum test for continuous variables and 
Chi-Square test for categorical variables. All statistical analysis was performed using SAS 
Statistical software. 
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Results 
 
A total of 31,854 patients were screened for study participation (Figure 1). Based on antibiotic 
exposure, length of stay less than 2 days, age less than 18 years, lack of serum creatinine values, 
baseline creatinine clearance greater than 4 times the standard deviation of the mean (~406 
mL/min) or less than 30 mL/min, days of therapy less than 2 days, and AKI prior to treatment 
index, within 48 hours of treatment index, or greater than 7 days after treatment was 
discontinued, 28,461 patients were excluded. The final sample consisted of 272 patients in the 
nafcillin study group and 3,121 patients in the piperacillin-tazobactam study group.  
 
Patient population 
 
The mean age of patients in the nafcillin group was 47.49 ± 15.61 years and 53.28 ± 17.56 years 
in the piperacillin-tazobactam group (p<0.0001) (Table 1). There were 64.34% males in the 
nafcillin group and 49.15% in the piperacillin-tazobactam group (<0.0001). Charlson 
Comorbidity Index was also statistically different between groups, with a mean score of 2.77 ± 
3.19 in the nafcillin group and 3.47 ± 3.65 in the piperacillin-tazobactam group (p=0.0084). 
Mean baseline creatinine clearance was 106.91 ± 42.73 mL/min in the nafcillin group and 100.38 
± 42.87 in the piperacillin-tazobactam group (p=0.0161). Hypotension was observed in 51 
(18.75%) of patients in the nafcillin group and 342 (10.96%) in the piperacillin-tazobactam 
group (p=0.0001). Exposure to concomitant nephrotoxins was significantly different for ACEIs, 
acyclovir, aminoglycosides, loop diuretics, NSAIDS, sulfonamides, tacrolimus, IV contrast, with 
all but tacrolimus being higher in nafcillin. There was no colistin use in either group. The 
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number of patients receiving 2, 3, and 4 or more concomitant nephrotoxins was also greater in 
the nafcillin group (p<0.0001). Mean duration of therapy was longer in the nafcillin group, 8.46 
± 9.96 days, compared to in the piperacillin-tazobactam group, 4.63 ± 2.67 days (p<0.0001). The 
number of patients transferred to University of Kentucky Healthcare from an outside hospital 
was 1,306 (38.49%), with a similar proportion in each group. There were no patients that 
developed need for dialysis while inpatient. 
 
Table 2 displays the antibiotic exposure for both study groups. In the nafcillin group, there were 
two patients (0.74%) who received piperacillin-tazobactam, 90 (33.09%) who received 
vancomycin, and 139 (51.10%) who received both piperacillin-tazobactam and vancomycin. 41 
(15.07%) patients received nafcillin only. 
 
Primary outcome 
 
In the unadjusted analysis, AKI occurred in 53 (19.49%) nafcillin patients and 241 (7.72%) 
piperacillin-tazobactam patients (p<0.0001). There were 38 (13.97%) patients classified as 
having risk in the nafcillin group and 192 (6.15%) in the piperacillin-tazobactam group. Ten 
(3.68%) of patients were classified as having injury in the nafcillin group and 37 (1.19%) in the 
piperacillin-tazobactam group. Finally, 5 (1.84%) were classified as having failure in the 
nafcillin group and 12 (0.38%) in the piperacillin-tazobactam group. All categories had higher 
incidence of nephrotoxicity in the nafcillin group. In the nafcillin only group, AKI occurred in 9 
patients (21.95%) compared to 241 (7.72%) in the piperacillin-tazobactam group (p<0.0001) 
(Table 3).  
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Adjustments were made for age, sex, Charlson Comorbidity Index, baseline creatinine clearance, 
hypotension, number of concomitant nephrotoxins, and duration of therapy. In the adjusted 
analysis, those in the nafcillin group had 2.002 (95% CI 1.357-2.953) times the odds of AKI 
compared to those in the piperacillin-tazobactam group. Results were similar in the risk category 
with the nafcillin group having 1.799 (95% CI 1.162-2.786) times the odds of risk compared to 
those in the piperacillin-tazobactam group. The injury and failure categories were non-significant 
with odds ratios of 2.246 (95% CI 0.958-5.264) and 2.357 (95% CI 0.685-8.113), respectively. 
The odds of AKI in the nafcillin only group was 2.634 (95% CI 1.154-6.016) times that of the 
piperacillin-tazobactam group (Table 4). 
 
Secondary outcomes  
 
The mean time to AKI was 6.00 ± 5.14 days in the nafcillin group and 4.69 ± 3.41 days in the 
piperacillin-tazobactam group (p=0.0458). The mean hospital length of stay was 14.38 ± 12.69 
days in the nafcillin group and 7.44 ± 7.55 days in the piperacillin-tazobactam group (p<0.0001). 
Mortality occurred in 135 (3.98%) patients in the total study population, with 23 (8.46%) in the 
nafcillin group and 112 (3.59%) in the piperacillin-tazobactam group (p<0.0001) (Table 5). 
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Discussion 
 
This study aimed to evaluate whether nephrotoxicity differs between nafcillin and piperacillin-
tazobactam. The nafcillin group had 2.002 (95% CI 1.357-2.953) times the odds of AKI 
compared to the piperacillin-tazobactam group after adjusting for age, sex, Charlson 
Comorbidity Index, baseline creatinine clearance, hypotension, number of concomitant 
nephrotoxins, and duration of therapy. This difference persisted in the risk category, however 
was not statistically significant in the injury and failure categories. A similar result was seen 
when limiting comparison to those who received nafcillin only. This study suggests that beta-
lactam antibiotics overall may contribute to nephrotoxicity in adult hospitalized patients, with 
nafcillin carrying a significantly larger burden of AKI than piperacillin-tazobactam.  
 
Results from this study agree with current literature, although the incidence of AKI in nafcillin 
was higher compared to previous studies. In a yet to be published study from the University of 
Kentucky, vancomycin in combination with piperacillin-tazobactam had a significantly higher 
incidence of nephrotoxicity than vancomycin in combination with cefepime, with rates of 30% 
and 18%, respectively (p<0.0001).14 The incidence of AKI was also shown to be different 
depending on the dosing scheme of piperacillin-tazobactam, with a higher rate in those who 
received 4.5 grams every 6 hours compared to those who received 3.375 grams every 6 hours. In 
a study evaluating a population of diabetic patients with osteomyelitis, acute renal failure was 
seen in 29.3% of patients being treated with combination of vancomycin with piperacillin-
tazobactam compared to 13.3% in patients treated with vancomycin in combination with 
cefepime. 29 In a third study, incidence of AKI was 34.8% in the vancomycin and piperacillin-
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tazobactam combination group compared to 12.5% in the vancomycin and cefepime group. 30 
There is also evidence of an increase in incidence of nephrotoxicity of vancomycin in 
combination with piperacillin-tazobactam compared to vancomycin alone.6,15,25,26 
 
There are a number of limitations associated with this study. This was a single center study 
conducted at University of Kentucky Healthcare and, therefore, results may not be generalizable 
to other hospitals serving different populations with differing levels of acuity. In addition, due to 
the retrospective nature of this study, there are many variables with potential to affect results that 
were unable to be collected, leading to residual confounding. One of these includes indication for 
antibiotics or microbiology results. Piperacillin-tazobactam is a broad-spectrum antibiotic that is 
often used for empiric therapy when an infection is suspected, however culture and 
susceptibilities or source of infection are unknown. Once more information is known about an 
infection, therapy is often switched to a more narrow-spectrum antibiotic such as nafcillin for an 
MSSA infection. This is likely the reason the number of patients in each group is different with 
the sample size in nafcillin being significantly smaller. This may also lead to nafcillin being used 
for longer durations compared to piperacillin-tazobactam, which may only be used for a short 
period of time before switching to an antibiotic targeting a specific bacterium.  
 
Another limitation is temporality. This study assessed exposure to concomitant nephrotoxins, 
hypotension, and dehydration at any point during a patient’s hospital stay rather than in relation 
to development of AKI. The amount and duration of exposure was not analyzed, and exposure to 
different nephrotoxins was treated the same and combined into a number of concomitant 
nephrotoxins group, although different medications may have differing levels of nephrotoxicity. 
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This study excluded patients in the piperacillin-tazobactam group who received vancomycin, 
however included patients in the nafcillin group if they received up to 5 days of therapy with 
vancomycin or piperacillin-tazobactam. This was due to the clinical use of nafcillin typically 
being after initial treatment with a more broad-spectrum antibiotic such as piperacillin-
tazobactam and/or vancomycin. The differing levels of exposure to vancomycin is another 
limitation of this study and may have an effect on the odds of nephrotoxicity in nafcillin. 
Exposure to vancomycin was excluded in the piperacillin-tazobactam group to try to isolate the 
effect of the study drug. However, nephrotoxicity due to vancomycin is not expected to develop 
within that timeframe;  it has been shown that nephrotoxicity occurs after 7 days of therapy.27 
Interestingly, time to AKI was longer in nafcillin, which is not what would be expected if 
exposure to vancomycin was contributing to this effect. 
 
Additionally, for patients transferred in from an outside hospital, information about their 
previous hospital stay prior to coming to University of Kentucky Healthcare was not available to 
be evaluated. 
 
Another possible limitation is use of the RIFLE criteria as a measure of nephrotoxicity. Prior to 
the introduction of the RIFLE criteria in 2004, a number of definitions of AKI were used. The 
RIFLE criteria has been largely validated to identify AKI, classify severity, and correlate with 
patient outcome.21-24 There has been an almost linear relationship seen between risk classification 
in the RIFLE criteria and hospital mortality.23 The RIFLE criteria is limited by its requirement of  
baseline renal function, or an estimate from the Modification of Diet in Renal Disease (MDRD) 
equation. It has been modified in an attempt to increase sensitivity and specificity with the Acute 
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Kidney Injury Network (AKIN) criteria, which was introduced in 2007. With the AKIN criteria, 
baseline serum creatinine is not required. However, AKIN criteria could not be used in this study 
because it requires adequate hydration status in order to diagnose AKI, which could not be 
ensured due to the retrospective nature of this study.28 Although these limitations exist, it has 
been shown that these two classification schemes are largely similar in identifying AKI and have 
no difference in ability to predict mortality.29-31 Creatinine clearance is used to estimate GFR, 
however it itself has limitations in its ability to measure kidney function. Biomarkers such as 
neutrophil gelatinase-associated lipocalin (NGAL) are currently being investigated as new ways 
to classify AKI earlier.32-34
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Conclusion 
 
The odds of AKI overall and risk classification were higher in the nafcillin group compared to 
the piperacillin-tazobactam group, although this difference did not persist in the injury and 
failure categories. The mean time to AKI and hospital length of stay were longer in nafcillin 
patients, and the incidence of mortality was also higher in the nafcillin group. This study 
suggests that beta-lactam antibiotics overall may contribute to nephrotoxicity in adult 
hospitalized patients, with nafcillin carrying a significantly greater potential for AKI than 
piperacillin-tazobactam. However, further analysis should be done to assess the impact of risk 
factors in contributing to this rate of nephrotoxicity since patients in the nafcillin group had 
greater exposure to concomitant nephrotoxins and a longer duration of therapy. Future research 
should further evaluate the findings of this study with a larger population assessing important 
variables that could not be analyzed, such as site and type of infection and time and duration of 
exposure to concomitant nephrotoxins, hypotension, and dehydration in relation to development 
of AKI. It may also be beneficial to compare other beta-lactams or different dosing schemes.  
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Tables and Figures 
 
Figure 1: Sample Selection 
 
 
 
 
31,854 total patients screened	

28,461 patients excluded:	

3,410 length of stay <2 days	

42 patient age <18 years	

15,211 patients did not receive nafcillin or piperacillin-tazobactam	

8,655 patients received piperacillin-tazobactam with vancomycin	

168 nafcillin patients with adjunct treatment >5 days	

40 patients with no serum creatinine values	

7 patients with baseline ClCr  >4*SD+mean (~406 mL/min)	

148 patients with baseline ClCr <30 mL/min	

553 patients with antibiotic days of therapy <2 days	

64 patients had an AKI prior to treatment index	

150  patients had an AKI within 48 hours of treatment index	

13 patients had an AKI >5 days after treatment discontinued	

272 patients in nafcillin study group	
3,121 patients in piperacillin-tazobactam study group	
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Table 1: Demographic and Clinical Characteristics 
Characteristic Overall 
n=3393 
Nafcillin group 
n=272 
Piperacillin-
tazobactam group 
n=3121 
p-value 
Age (years)a,b 
 
52.82 ± 17.48 
54 (25)  
47.49 ± 15.61 
47 (22) 
53.28 ± 17.56 
54 (26) 
<0.0001c 
Male sex 
 
1709 (50.37) 175 (64.34) 1534 (49.15) <0.0001e 
Charlson 
Comorbidity 
Indexa,b 
3.42 ± 3.62 
2 (4)  
2.77 ± 3.19 
2 (3) 
3.47 ± 3.65 
2 (4) 
0.0084d 
Baseline ClCr  
(mL/min)a,b 
 
100.91 ± 42.89 
95 (54.85)  
 
106.9 ± 42.73 
102.39 (54.69) 
100.4 ± 42.87 
94.36 (54.48) 
0.0161c 
Dehydration 
 
233 (6.87) 15 (5.51) 218 (6.98) 0.3578e 
Hypotension 
 
393 (11.58) 51 (18.75) 342 (10.96) 0.0001e 
Concomitant 
nephrotoxins 
    
ACEI 609 (17.95) 63 (23.16) 546 (17.49) 0.0195e 
ARB 142 (4.19) 9 (3.31) 133 (4.26) 0.4518e 
Acyclovir 28 (0.83) 8 (2.94) 20 (0.64) 0.0012f 
Aminoglycosides 165 (4.86) 28 (10.29) 137 (4.39) <0.0001e 
Amphotericin B 14 (0.41) 3 (1.10) 11 (0.35) 0.0959f 
Cyclosporine  13 (0.38) 1 (0.37) 12 (0.38) 1.0000f 
Foscarnet 1 (0.03) 0 (0.00) 1 (0.03) 1.0000f 
Loop diuretics 679 (20.01) 67 (24.63) 612 (19.61) 0.0470e 
NSAIDs 365 (10.76) 54 (19.85) 311 (9.96) <0.0001e 
Sulfonamides 25 (0.74) 7 (2.57) 18 (0.58) 0.0027f 
Tacrolimus 69  (2.03) 0 (0.00) 69 (2.21) 0.0057f 
Tenofovir 22 (0.65) 4 (1.47) 18 (0.58) 0.0940f 
IV contrast  1666 (49.10) 163 (59.93) 1503 (48.16) 0.0002e 
Number of 
concomitant 
nephrotoxins 
   <0.0001e 
0 895 (26.38) 53 (19.49) 842 (26.98)  
1 1476 (43.50) 91 (33.46) 1385 (44.38)  
2 784 (23.11) 78 (28.68) 706 (22.62)  
3 203 (5.98) 40 (14.71) 163 (5.22)  
4+ 35 (1.03) 10 (3.68) 25 (0.80)  
Duration of 
Therapy (days)a,b 
4.93 ± 3.95 
4 (3) 
8.46 ± 9.96 
5 (7) 
4.63 ± 2.67 
4 (3) 
<0.0001d 
Data are number (percentage) unless otherwise indicated. ACEI = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ClCr = 
creatinine clearance (adjusted Cockcroft-Gault); NSAID = non-steroidal anti-inflammatory drug; IV = intravenous. 
aMean ± Standard Deviation, bMedian (Interquartile Range), cStudent’s T-test, dWilcoxon Rank Sum Test, eChi-Square Test, fFisher’s Exact Test 
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Table 2: Antibiotic Exposure 
Study Group Antibiotic Frequency 
Nafcillin group Nafcillin only 41 (15.07) 
Nafcillin + Piperacillin-tazobactam 2 (0.74) 
Nafcillin + Vancomycin 90 (33.09) 
Nafcillin + Piperacillin-tazobactam + 
Vancomycin 
139 (51.10) 
Piperacillin-tazobactam 
group 
Piperacillin-tazobactam only 3121 (100.00) 
Data are number (percentage) unless otherwise indicated. 
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Table 3: Cumulative Incidence of Acute Kidney Injury (Unadjusted) 
Nafcillin with Concomitant Antibiotics ≤5 days vs. Piperacillin-tazobactam 
Characteristic Overall 
n=3,393 
Nafcillin group 
n=272 
Piperacillin-
tazobactam group 
n=3,121 
p-value 
Acute Kidney 
Injury, overall 
294 (8.66) 53 (19.49) 241 (7.72) <0.0001a 
Risk 230 (6.78) 38 (13.97) 192 (6.15)  
Injury 47 (1.39) 10 (3.68) 37 (1.19)  
Failure 17 (0.50) 5 (1.84) 12 (0.38)  
Nafcillin only vs. Piperacillin-tazobactam 
Characteristic NAF 
n=41 
NP 
n=2 
NV 
n=90 
NPV 
n=139 
PTZ 
n=3121 
p-value 
Acute Kidney 
Injury, overall 
9 (21.95) 0 (0.00) 16 (17.78) 28 (20.14) 241 (7.72) <0.0001b 
Risk 7 (17.07) 0 (0.00) 11 (12.22) 20 (14.39) 192 (6.15)  
Injury 1 (2.44) 0 (0.00) 4 (4.44) 5 (3.60) 37 (1.19)  
Failure 1 (2.44) 0 (0.00) 1 (1.11) 3 (2.16) 12 (0.38)  
Data are number (percentage) unless otherwise indicated. NAF = nafcillin only; NP = nafcillin + piperacillin-tazobactam; NV = nafcillin + 
vancomycin; NPV = nafcillin + piperacillin-tazobactam + vancomycin. 
aChi-Square Test 
bFisher’s Exact Test 
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Table 4: Adjusted Odds Ratio for Acute Kidney Injury for Nafcillin as compared to 
Piperacillin-tazobactam 
Nafcillin with Concomitant Antibiotics ≤5 days vs. Piperacillin-tazobactam 
Primary Outcome Odds Ratio (OR) 95% Confidence Interval 
Acute Kidney Injury, 
overall 
2.002 1.357 2.953 
Risk 1.799 1.162 2.786 
Injury 2.246 0.958 5.264 
Failure 2.357 0.685 8.113 
Nafcillin only vs. Piperacillin-tazobactam 
Primary Outcome Odds Ratio (OR) 95% Confidence Interval 
Acute Kidney Injury, 
overall 
2.634 1.154 6.016 
Data analyzed using logistic regression. Adjusted for age, sex, Charlson Comorbidity Index, baseline creatinine clearance, hypotension, number 
of concomitant nephrotoxins, and duration of therapy. 
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Table 5: Time to Acute Kidney Injury, Hospital Length of Stay, and Mortality 
 Overall 
n=294 
Nafcillin group 
n=53 
Piperacillin-
tazobactam group 
n=241 
 
p-value 
Time to Acute 
Kidney Injurya,b 
4.93 ± 3.80 
4 (4) 
6.00 ± 5.14 
5 (4) 
4.69 ± 3.41 
4 (4) 
0.0458c 
     
 Overall 
n=3,393 
Nafcillin group 
n=272 
Piperacillin-
tazobactam group 
n=3,121 
p-value 
Hospital Length 
of Staya,b 
8.00 ± 8.30 
5 (6) 
14.38 ± 12.69 
10 (11) 
7.44 ± 7.55 
5 (6) 
<0.0001c 
Mortality 135 (3.98) 23 (8.46) 112 (3.59) <0.0001d 
Data are number (percentage) unless otherwise indicated. 
aMean ± Standard Deviation, bMedian (Interquartile Range), cWilcoxon Rank Sum Test, dChi-Square Test 
 
 
30 
Acknowledgements 
 
The completion of this capstone project would not have been possible without the help of 
numerous faculty members, friends, family, and peers. I would especially like to express my 
sincere gratitude to Dr. Daniela Moga and Dr. Craig Martin for their continued mentorship and 
guidance throughout the years. Your patience, encouragement, and expertise are greatly 
appreciated. I would also like to thank Dr. Cliff Rutter for his insight and assistance with my 
project, and the rest of my capstone committee, Dr. Lorie Chesnut and Dr. David Mannino, for 
their time and feedback. Finally, I would like to thank my parents, Kishor and Priti Patel, for 
their endless love and support in everything I do. I owe my success to you. 
 
I have no relevant financial or material support to disclose.  
 
This study was exempt from IRB approval as only de-identified data were used. 
  
31 
Biographical Sketch  
 
Sonali Kishor Patel is a fourth year Doctor of Pharmacy student at the University of Kentucky 
College of Pharmacy. She is participating in a dual degree program working towards a Master of 
Public Health with a concentration in epidemiology at the University of Kentucky College of 
Public Health. Sonali is currently employed as a pharmacy intern at Walmart Pharmacy. 
Professional affiliations include Rho Chi Honor Society, Kentucky Alliance of Pharmacy 
Students, Lambda Kappa Sigma, American Pharmacists Association, Kentucky Pharmacists 
Association, American Society of Health-System Pharmacists, Kentucky Society of Health-
System Pharmacists, and National Community Pharmacists Association. After graduation, Sonali 
will be completing a Post-Graduate Year 1 pharmacy residency at Grady Memorial Hospital in 
Atlanta, Georgia. With interests in infectious diseases and academia, Sonali’s long-term career 
goal is to become an infectious diseases clinical pharmacist and adjunct faculty member. 
 
Contact Information: 
860 Wolf Hills Boulevard 
Henderson, Kentucky 42420 
(920) 238-7095 
sonals91@gmail.com 
 
